CN114010641A - 用于治疗神经病症的方法 - Google Patents

用于治疗神经病症的方法 Download PDF

Info

Publication number
CN114010641A
CN114010641A CN202110783304.XA CN202110783304A CN114010641A CN 114010641 A CN114010641 A CN 114010641A CN 202110783304 A CN202110783304 A CN 202110783304A CN 114010641 A CN114010641 A CN 114010641A
Authority
CN
China
Prior art keywords
rats
dose
pharmaceutically acceptable
day
acceptable composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202110783304.XA
Other languages
English (en)
Chinese (zh)
Inventor
约翰·贾汉吉尔·阿拉姆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
EIP Pharma LLC
Original Assignee
EIP Pharma LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by EIP Pharma LLC filed Critical EIP Pharma LLC
Publication of CN114010641A publication Critical patent/CN114010641A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202110783304.XA 2014-07-09 2015-07-08 用于治疗神经病症的方法 Pending CN114010641A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462022586P 2014-07-09 2014-07-09
US62/022,586 2014-07-09
CN201580037336.8A CN106659723A (zh) 2014-07-09 2015-07-08 用于治疗神经病症的方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201580037336.8A Division CN106659723A (zh) 2014-07-09 2015-07-08 用于治疗神经病症的方法

Publications (1)

Publication Number Publication Date
CN114010641A true CN114010641A (zh) 2022-02-08

Family

ID=55064826

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202110783304.XA Pending CN114010641A (zh) 2014-07-09 2015-07-08 用于治疗神经病症的方法
CN202110348688.2A Active CN113018300B (zh) 2014-07-09 2015-07-08 用于治疗神经病症的方法
CN201580037336.8A Pending CN106659723A (zh) 2014-07-09 2015-07-08 用于治疗神经病症的方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202110348688.2A Active CN113018300B (zh) 2014-07-09 2015-07-08 用于治疗神经病症的方法
CN201580037336.8A Pending CN106659723A (zh) 2014-07-09 2015-07-08 用于治疗神经病症的方法

Country Status (5)

Country Link
US (1) US9579322B2 (enExample)
EP (1) EP3166610B1 (enExample)
JP (1) JP6660369B2 (enExample)
CN (3) CN114010641A (enExample)
WO (1) WO2016007616A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3166610B1 (en) 2014-07-09 2022-11-02 Eip Pharma, LLC Methods for treating neurologic disorders
JP6889493B2 (ja) * 2015-10-26 2021-06-18 イーアイピー ファーマ， エルエルシー 脳卒中からの回復のための方法および組成物
EP3445369A4 (en) 2016-04-21 2020-03-04 Eip Pharma, LLC COMPOSITIONS AND METHODS FOR TREATING DEMENTIA
WO2019056003A1 (en) 2017-09-18 2019-03-21 Eip Pharma, Llc CO-CRYSTALS FROM NEFLAMAPIMOD (VX -745)
PT3691620T (pt) 2017-10-05 2022-10-06 Fulcrum Therapeutics Inc Os inibidores da quinase p38 reduzem a expressão de dux4 e genes a jusante para o tratamento de fshd
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
WO2019178153A1 (en) * 2018-03-12 2019-09-19 Eip Pharma, Llc Pharmaceutical formulations of neflamapimod
MX2021005801A (es) * 2018-11-20 2021-08-05 Sparrow Pharmaceuticals Inc Metodos para administrar corticosteroides.
EP3986396A4 (en) * 2019-06-18 2023-08-02 Opiant Pharmaceuticals, Inc. COMPOSITIONS AND METHODS FOR TREATMENT OF ACUTE CANNABINOID OVERDOSE WITH A CANNABINOID RECEPTOR ANTAGONIST
US11471437B2 (en) 2019-06-18 2022-10-18 Opiant Pharmaceuticals, Inc. Compositions and methods for treating cannabinoid hyperemesis syndrome with a cannabinoid receptor antagonist
CN115066245A (zh) * 2019-07-12 2022-09-16 Eip制药公司 用于治疗路易体痴呆的组合物和方法
CA3200988A1 (en) * 2020-11-06 2022-05-12 John Jahangir Alam Treatment of gait dysfunction in neurodegenerative disease
CN113616795B (zh) * 2021-08-31 2023-06-20 上海交通大学医学院附属瑞金医院 Pp2a激动剂防治由正常衰老或pp2a活性或表达降低所导致的精神障碍
US20240358962A1 (en) * 2023-04-27 2024-10-31 Remepy Health Ltd Digital therapeutics for improved immune function

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101103969A (zh) * 2002-12-24 2008-01-16 神经化学（国际）有限公司 治疗β淀粉样蛋白相关疾病的治疗性制品
CN103842362A (zh) * 2011-05-09 2014-06-04 爱普制药有限责任公司 用于治疗阿尔茨海默氏病的组合物和方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6147080A (en) 1996-12-18 2000-11-14 Vertex Pharmaceuticals Incorporated Inhibitors of p38
US20050203111A1 (en) 2004-03-12 2005-09-15 Vvii Newco 2003, Inc. Compositions and methods for preventing and treating skin and hair conditions
JP2007528393A (ja) 2004-03-11 2007-10-11 カイセラ バイオファーマシューティカルズ， インコーポレイテッド 皮膚の状態および毛の状態を予防および処置するための組成物および方法
JP2009514851A (ja) 2005-11-08 2009-04-09 ランバクシー ラボラトリーズ リミテッド （３ｒ，５ｒ）−７−［２−（４−フルオロフェニル）−５−イソプロピル−３−フェニル−４−［（４−ヒドロキシメチルフェニルアミノ）カルボニル］−ピロール−１−イル］−３，５−ジヒドロキシ−ヘプタン酸ヘミカルシウム塩の製法
CA2655632A1 (en) 2006-06-23 2008-01-03 The Feinstein Institute For Medical Research Inhibitors of a.beta. and synuclein aggregation
US8304413B2 (en) * 2008-06-03 2012-11-06 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
BR112013025798A2 (pt) * 2011-04-08 2016-12-20 Afraxis Holdings Inc 8-etil-6-(aril)pirido[2,3-d]pirimidin-7(8h)-onas para o tratamento de câncer e distúrbios de sistema nervoso
EP3166610B1 (en) 2014-07-09 2022-11-02 Eip Pharma, LLC Methods for treating neurologic disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101103969A (zh) * 2002-12-24 2008-01-16 神经化学（国际）有限公司 治疗β淀粉样蛋白相关疾病的治疗性制品
CN103842362A (zh) * 2011-05-09 2014-06-04 爱普制药有限责任公司 用于治疗阿尔茨海默氏病的组合物和方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KUMAR S等: "p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases", NATURE REVIEWS DRUG DISCOVER, vol. 02, no. 09, 1 September 2003 (2003-09-01), pages 724 *

Also Published As

Publication number Publication date
JP6660369B2 (ja) 2020-03-11
WO2016007616A1 (en) 2016-01-14
US20160008364A1 (en) 2016-01-14
CN113018300A (zh) 2021-06-25
CN106659723A (zh) 2017-05-10
EP3166610B1 (en) 2022-11-02
JP2017519807A (ja) 2017-07-20
CN113018300B (zh) 2025-11-25
US9579322B2 (en) 2017-02-28
EP3166610A4 (en) 2017-11-29
EP3166610A1 (en) 2017-05-17

Similar Documents

Publication Publication Date Title
CN114010641A (zh) 用于治疗神经病症的方法
CN103842362B (zh) 用于治疗阿尔茨海默氏病的组合物和方法
JP2021100951A (ja) 過敏性腸症候群および末梢神経系の他の病気の治療のための末梢限局性ｇａｂａポジティブアロステリックモジュレーター
JP2010511616A (ja) 水素化ピリド（４，３−ｂ）インドール（異性体）に基づいた認知機能および記憶を改善するための手段、当該手段に基づいた薬理学的手段、および当該手段の使用のための方法
JP2020513005A (ja) Ｃｃｒ３阻害剤を用いて、加齢性機能障害を治療するための方法及び組成物
CA2601509A1 (en) Alpha7 neuronal nicotinic receptor ligand and antipsychotic compositions
JP2013531073A (ja) シグマ受容体に仲介される障害を処置するための環状アミド誘導体の使用の方法
KR102891465B1 (ko) 뇌졸중으로부터의 회복을 위한 방법 및 조성물
JP6959371B2 (ja) 純粋な５−ｈｔ６受容体アンタゴニストの新たな使用
JP2010531854A (ja) 抗アミロイド剤としてのピレンゼピンおよびその誘導体
JP2019516699A (ja) 純粋な５−ｈｔ６受容体アンタゴニストとアセチルコリンエステラーゼ阻害剤の組合せ
HK40068517A (en) Methods for treating neurologic disorders
BR112020022377A2 (pt) método para o tratamento da dor ou cistite intersticial usando um composto indol
JP6606298B2 (ja) 純粋な５−ｈｔ６受容体アンタゴニストのｎｍｄａ受容体アンタゴニストとの組合せ
JP6629464B2 (ja) 純粋な５−ｈｔ６受容体アンタゴニスト、アセチルコリンエステラーゼ阻害剤及びｎｍｄａ受容体アンタゴニストの３種類の組合せ
Janssen et al. Influence of 5-HT1 receptor agonists on feline stomach relaxation
BR112019012821A2 (pt) derivados de benzodiazepina, composições e métodos para o tratamento do comprometimento cognitivo
MX2010006520A (es) Metodo y composicion para el tratamiento de una condicion mediada por alfa-adrenoceptor.
CN112789044A (zh) 使用ccr3-抑制剂治疗衰老相关损伤的方法及组合物
WO2025229051A1 (en) Use of atr inhibitors in combination with antiandrogen agent
HK40019123A (en) Methods and compositions for treating aging-associated impairments using ccr3-inhibitors
JP2023060149A (ja) ５－ｈｔ４受容体アゴニストの新しい使用
HK40053020A (en) Methods and compositions for treating aging-associated impairments using ccr3-inhibitors
EA042685B1 (ru) Новые применения чистого антагониста 5-ht6 рецептора
CA2567397A1 (en) Use of neboglamine (cr 2249) as an antipsychotic and neuroprotective

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40068517

Country of ref document: HK